A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 (10 or 20 mg/kg) Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic (Stage IIIb With Pleural Effusion or Stage IV) Non-Squamous Non-Small-Cell Lung Cancer

Registry ID

EUCTR2005-001731-30

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

UCB Celltech

Start date

2005-07-25

Completion date

2009-06-25

Last update

2026-08-16

Conditions

• Non squamous non small cell lung cancer

Summary

Part 1: To evaluate safety and tolerability of CDP791 given at 10 and 20 mg/kg in combination with carboplatin/paclitaxel in subjects with locally advanced and metastatic (Stage IIIb with malignant pleural effusion or Stage IV) non-squamous non-small-cell lung cancer (NSCLC).Part 2: To compare the tumor response rate of CDP791 given at 10 and 20 mg/kg in combination with carboplatin/paclitaxel with that of carboplatin/paclitaxel alone, in subjects with locally advanced and metastatic (Stage IIIb with malignant pleural effusion or stage IV) non-squamous non-small-cell lung cancer (NSCLC).

Locations

• , , Hungary

View on source registry